The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.

An in vitro cell culture substrate is disclosed. The substrate comprises a decellularized tissue-specific extracellular matrix, wherein the tissue-specific extracellular matrix is derived from fibrotic tissue. A method of method of assessing an in vitro fibrotic cell culture is also disclosed. The method comprises providing one or more substrates comprising decellularized tissue-specific extracellular matrix derived from fibrotic tissue, where each substrate is provided in segregated manner. The method further comprises culturing native cells in each substrate to form a fibrotic cell culture. The method further comprises assessing at least one characteristic of each fibrotic cell culture.

Platelet lysate compositions and cell culture media compositions for maintaining and/or growing mammalian cells, such as mammalian endothelial cells (ECs) and mammalian endothelial progenitor cells (EPCs), in particular human ECs (huECs) and human EPCs (huEPCs), such as primary huECs and primary huEPCs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors. Also provided are methods for making and using such cell culture media compositions to grow and/or maintain ECs and EPCs, including huECs and huEPCs, as well as cell culture vessels, dishes, plates, and/or flasks pretreated with the cell culture media compositions.

A method for the ex vivo cultivation of oral mucosal epithelial progenitor cells and oral mucosal epithelial cells includes: subjecting an oral mucosal tissue to an enzymatic digestion treatment with collagenase, so as to obtain cell aggregates which include oral mucosal epithelial progenitor cells and oral mucosal epithelial cells; cultivating the cell aggregates with an amniotic membrane in a serum-free platelet lysate-containing medium in the absence of feeder cells, so that the cell aggregates are adhered onto the amniotic membrane; and subsequently cultivating the cell aggregates adhered on the amniotic membrane in a serum-free proliferation-facilitating medium in the absence of feeder cells.

The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.

The present disclosure relates to the technical field of microorganisms, in particular to Lactobacillus gasseri HMV18 and an exocrine protein and an application thereof. The Lactobacillus gasseri HMV18 is preserved in the China Center for Type Culture Collection on Jul. 11, 2019 with a preservation number of CCTCC NO: M 2019538, and a preservation address of Wuhan University, Wuhan, China. The protein extracted from the Lactobacillus gasseri HMV18 has antibacterial and anti-tumor effects, but basically has no effect on normal myocardial cells, so the Lactobacillus gasseri HMV18 can be applied to preparation of antibacterial and anti-tumor products.

The present invention relates to: a method for preparing a stem cell culture solution which contains growth factors and cytokines and is obtained by culturing, in a serum-free medium, mesenchymal stem cells cultured in a medium containing human platelet lysates (hPLs); and a cosmetic composition using the stem cell culture solution. When the method for preparing a mesenchymal stem cell culture solution obtained from mesenchymal stem cells cultured in an hPL-containing medium is used, it is possible to obtain a mesenchymal stem cell culture solution which has a higher amount of cytokines and growth factors than that of a mesenchymal stem cell culture solution obtained from mesenchymal stem cells cultured in an FBS-containing medium, and has excellent efficacy in the promotion of human dermal fibroblast proliferation, collagen synthesis, elastin synthesis, inhibition of melanin synthesis, and hair growth. The mesenchymal stem cell culture solution can be used to produce cosmetics having effects of skin regeneration, wrinkle improvement, skin elasticity enhancement, skin whitening, and hair growth, and thus can be widely used in the cosmetic field and the pharmaceutical industry.

The present disclosure relates to a cryopreserved pharmaceutical composition comprising immature dental pulp stem cells (IDPSCs) expressing SOX-1 and SOX-2 and methods of treating a neurological disease or condition comprising systemically administering to a subject a cryopreserved pharmaceutical composition comprising IDPSCs expressing SOX-1 and SOX-2.

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.